TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III~* Original clinical staged as T1-4N1-3 or T3-4N0（according to the 7th AJCC edition）~* No evidence of distant metastasis (M0)~* Male and no pregnant female~* Age between 18-65~* WBC ≥ 4,000/mm3 and PLT ≥ 100,000/mm3~* With normal liver function test (ALT、AST ≤ 2.5×ULN)~* With normal renal function test (Creatinine ≤ 1.5×ULN)~* Satisfactory performance status: Karnofsky scale (KPS)\> 70~* Without radiotherapy or chemotherapy~* Patients must give signed informed consent~Exclusion Criteria:~* Patients have evidence of relapse or distant metastasis~* The presence of uncontrolled life-threatening illness~* Receiving other ways of anti-cancer therapy~* Receiving radiotherapy or chemotherapy~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Nedaplatin (Type: EXPERIMENTAL): Nedplatin combine with IMRT
- Cisplatin (Type: ACTIVE_COMPARATOR): Cisplatin combine with IMRT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have chronic genotype 1 HCV infection with HCV RNA level \>= 5.0 log10 IU/mL~* Patient has never received treatment for HCV (treatment-naive), relapsed after previous IFN-based therapy (prior relapser) or failed to respond to previous IFN-based therapy (non-responder)~* Patient must be willing to use contraceptive measures from the time of informed consent to 6 months after last dose of study medication.~Exclusion Criteria:~* Co-infection with any other HCV genotype or co-infection with the human immunodeficiency virus (HIV)~* Diagnosed with hepatic cirrhosis or hepatic failure~* A medical condition which is a contraindication to peg-IFN or ribavirin therapy~* History of, or any current medical condition, which could impact the safety of the patient in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
- Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48 (Type: EXPERIMENTAL): Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels \<1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
- Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48 (Type: EXPERIMENTAL): Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 5-10 years (±3 months)~* permanent residents of the area~* absence of history of hypersensitivity reactions to the drugs~Exclusion Criteria:~* chronic illness~* severe malnutrition (weight-for-age nutritional Z score \[WAZ\] \<60th percentile)~* severe anemia (Hb \<5 g/dL),~* G-6-PD deficiency (\<60% G-6-PD activity)~* permanent disability, which prevents or impedes study participation. Any 1 or more of the criteria is sufficient to exclude study participation.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- Primaquine (Type: ACTIVE_COMPARATOR): Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood Glucose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female healthy volunteers must be post-menopausal (cessation of menses \>1year, be surgically sterile (documented) or have undergone hysterectomy) or be sexually abstinent from enrolment until follow-up examination~* Have normal physical exam, vital signs ECG findings, and laboratory values~Exclusion Criteria:~* Use of prescription medication for a chronic or acute medical condition within 3 weeks of randomization~* History or presence of neurological, haematological, psychiatric, gastrointestinal, hepatic or renal disease, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs as determined by the Investigator~* Previous participation in an AstraZeneca (AZ) or Bristol-Myers Squibb (BMS) dapagliflozin study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 42 to 70 days at enrollment.~* Determined by medical history, physical examination, and clinical judgment to be eligible for the study~* Weight of 3.5 kg or greater at the time of enrollment~Exclusion Criteria:~* Previous vaccination with licensed or investigational pneumococcal vaccine.~* A previous anaphylactic reaction to any vaccine or vaccine-related component.~* Contraindication to vaccination with pneumococcal conjugate vaccine.~* Receipt of blood products or gamma-globulin since birth

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 70 Days
- Healthy Volunteers: t

Study Arms:
- Multidose Vial Group (Type: EXPERIMENTAL): Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
- Single-Dose Syringe Group (Type: ACTIVE_COMPARATOR): Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Local Anesthetic Treatment of Oral Pain in Patients With Mucositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with head/neck cancer and starting radio therapy treatment~* age between 18 and 80 years (both included)~* able to talk, read and understand Danish~* ability to give informed consent~Exclusion Criteria:~* known hypersensitivity towards bupivacaine or other local anesthetics of the amide type~* pregnancy~* women breastfeeding a child

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bupivacaine lozenge (Type: ACTIVE_COMPARATOR): The patients can take up to eight 25 mg bupivacaine lozenges (max. every second hour in the awake hours) a day for seven days. The patients can use concomitant systemic pain treatment (e.g. morphine).
- Standard treatment (Type: OTHER): The patients will be treated with the currently used standard pain treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin). The anesthetics are being administered at the physician's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy which is due to diabetes~* Stable glycemic control for at least 6 months prior to screening visit~* Average Numeric Pain Rating Scale (NPRS) score over the last 24 hours of \>4 at the screening and the baseline visit~Exclusion Criteria:~* Primary pain associated with PDPN in the ankles or above~* Pain that could not be clearly differentiated from, or conditions that might interfere with, the assessment of PDPN~* Significant pain (moderate or above) of an etiology other than PDPN, that may interfere with judging PDPN-related pain~* Female subjects of childbearing potential must have a negative serum or urine pregnancy test at enrollment and must agree to maintain highly effective birth control during the study.~* Hypersensitivity to capsaicin (i.e., chili peppers or over-the-counter \[OTC\] capsaicin products), any QUTENZA excipients, Eutectic Mixture of Local Anesthetics( EMLA) ingredients or adhesives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Qutenza 30 minutes + SOC (Type: EXPERIMENTAL): None
- 2. Qutenza 60 minutes + SOC (Type: EXPERIMENTAL): None
- 3. SOC (Type: NO_INTERVENTION): Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - POPLAR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult participants, \>/= 18 years of age~* Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) non-small cell lung cancer (NSCLC)~* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens~* Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen~* Measurable disease, as defined by RECIST v1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Known active or untreated central nervous system (CNS) metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments~* Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome~* History of autoimmune disease~* History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.~* Active hepatitis B or hepatitis C~* Prior treatment with docetaxel~* Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel (Type: ACTIVE_COMPARATOR): Participants received docetaxel 75 milligram per meter square (mg/m\^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
- Atezolizumab (Type: EXPERIMENTAL): Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Life 2: Improving Fitness and Function in Elders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 70 or over~* Followed in VA primary care or geriatrics clinic~* Currently not regularly physically active~* Able to walk 10 meters without human assistance (assistive device acceptable)~Exclusion Criteria:~* Age 70 or over~* Followed in VA primary care or geriatrics clinic~* Currently not regularly physically active~* Able to walk 10 meters without human assistance (assistive device acceptable)~* A terminal diagnosis

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Behavioral: Multi-component physical activity counseling program A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
- Arm 2 (Type: NO_INTERVENTION): Usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age;~* rheumatoid arthritis for \>=3 months and \<=10 years;~* inadequate response to methotrexate (12.5-25mg/week) for \>=3 months;~* evidence of erosive disease and/or clinical synovitis in a signal joint.~Exclusion Criteria:~* autoimmune rheumatic diseases other than RA;~* surgical operations on bones/joints in 12 weeks prior to baseline visit;~* concomitant treatment with biologic agents;~* previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Obese Patients With or Without Comorbidities (RIO-North America)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
* Stable weight (variation of less than 5 kg within 3 months prior to screening visit)~* BMI (Body Mass Index) of 30 or greater in patients with or without comorbidities, or BMI greater than 27 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remission in Subjects With Crohn's Disease, 1 Year Phase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion:~* Patient must have successfully completed the induction study NCT00055523~* Diagnosis of Crohn's disease~* Willing and able to give informed consent~Exclusion:~* Diagnosis of ulcerative colitis~* Pregnancy or breastfeeding~* Previous use of infliximab or other anti-TNF antagonists~* Previous history of active tuberculosis or listeria infection~* Previous history of cancer other than successfully treated skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Double-blind (DB) adalimumab placebo (Type: PLACEBO_COMPARATOR): Double-blind nonactive matching subcutaneous injection
- Double-blind adalimumab 40 mg every other week (eow) (Type: EXPERIMENTAL): Double-blind adalimumab 40 mg eow by subcutaneous injection
- Double-blind adalimumab 40 mg every week (ew) (Type: EXPERIMENTAL): Double-blind adalimumab 40 mg every week by subcutaneous injection
- Open-label adalimumab 40 mg (Type: EXPERIMENTAL): Open-label adalimumab 40 mg eow or ew by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Chronic low platelet count between 20,000 and \<70,000/µL.~* Prior liver biopsy indicating chronic hepatitis within the previous 5 years or radiographic evidence of cirrhosis and / or endoscopic evidence of non-bleeding esophageal or gastric varices.~Exclusion criteria:~* History of heart attack or abnormal heart function.~* History of thrombosis within 1 year.~* History of alcohol or drug abuse or dependence within 1 year.~* Use of aspirin, aspirin-containing compounds, salicylates, antacids.~* History of HIV infection or active infection with Hepatitis B or C.~* Females who are pregnant.~* Patients using non-steroidal anti-inflammatory drugs during the study and within 3 weeks prior to starting the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm B (Type: ACTIVE_COMPARATOR): SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
- Arm C (Type: ACTIVE_COMPARATOR): SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
- Arm D (Type: ACTIVE_COMPARATOR): SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
- Arm A (Type: PLACEBO_COMPARATOR): Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete